Fig. 2

PepO treatment suppresses TNBC growth in vivo. A Schematic of the TNBC model and PepO/PBS treatment regimen. At the end of the experiments, mice were sacrificed, and the anticancer effects in each group were evaluated and compared (n = 5). B Tumor growth profiles in different treatment groups, and the tumor weights at the end of the experiment was recorded (n = 5). C Schematic of the secondary tumorigenesis and statistics table of tumorigenicity. D, E Tumor tissues were excised, fixed and sectioned. TUNEL staining of tumor tissues from each group was used to evaluate the apoptosis of tumor cells (scale bar = 1000 μm). Cell proliferation (Ki-67) was evaluated using Immunofluorescence detection (scale bar = 20 μm). F Flow cytometry was used to analize the phase of the tumor cell cycle from tumor tissue treated by PepO or PBS congtrol. The mean cell ratios at every phases were shown in the right graph. G Left, immunofluorescent triple staining for E-cadherin (green), Snail (pink), Vimentin (red) in TNBC tissue established by PY8119. Right, western blot detection of EMT markers in tumor tissue treated or untreated by PepO. Two-way repeated-measures ANOVA with Sidak’s multiple comparisons test was used in (B, Tumor growth profiles), and one-way ANOVA with Tukey’s multiple comparisons test was used in (B, tumor weights). Bar graphs represent mean ± SEM, *P < 0.05, **P < 0.01